See up to 3 months of GRAL. The 7-day demo opens the 1M and 3M ranges and puts GRAL on your watchlist.
Start 7-day demoLatest GRAL insider trades
About GRAIL, Inc. (GRAL)
GRAIL, Inc. is an SEC registrant, filing under CIK 0001699031, classified as medical laboratories. We track it alongside the rest of the Health Care sector.
GRAL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 109,944 | $12.10M |
| Option exercise | 2 | 52,904 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
GRAL insider transactions (Form 4)
3670 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Joshua J. Ofman - Officer | Open-market sale | Common Stock | 13,000 | $100.00 | $1.30M | |
| Aaron Freidin - Officer | Open-market sale | Common Stock | 25,000 | $99.15 footnote F1 | $2.48M | |
| ||||||
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 14,807 | $94.43 footnote F1 | $1.40M | |
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 15,356 | $95.28 footnote F3 | $1.46M | |
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 8,233 | $96.22 footnote F4 | $792K | |
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 1,604 | $97.28 footnote F5 | $156K | |
| ||||||
| Aaron Freidin - Officer | Open-market sale | Common Stock | 1,697 | $79.20 footnote F1 | $134K | |
| ||||||
| ILLUMINA, INC. | Open-market sale | Common stock, par value $0.001 per share | 1,000,000 | $79.85 | $79.85M | |
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 8,865 | $76.03 | $674K | |
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 6,114 | $82.01 | $501K | |
 William J. Chase - Director | Grant or award | Common Stock | 275 footnote F1 | $75.52 | $21K | |
| ||||||
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 7,239 | $68.88 footnote F1 | $499K | |
| ||||||
 Steven Mizell - Director | Grant or award | Common Stock | 267 footnote F1 | $75.52 | $20K | |
| ||||||
 Gregory L. Summe - Director | Grant or award | Common Stock | 425 footnote F1 | $75.52 | $32K | |
| ||||||
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 81,385 | $62.50 footnote F1 | $5.09M | |
| ||||||
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 9,692 | $64.00 | $620K | |
| Aaron Freidin - Officer | Open-market sale | Common Stock | 877 | $32.02 | $28K | |
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 4,202 | $32.02 | $135K | |
| Aaron Freidin - Officer | Open-market sale | Common Stock | 8,000 | $38.93 | $311K | |
| William J. Chase - Director | Grant or award | Common Stock | 533 | $38.53 | $21K | |
| Steven Mizell - Director | Grant or award | Common Stock | 517 | $38.53 | $20K | |
| Gregory L. Summe - Director | Grant or award | Common Stock | 825 | $38.53 | $32K | |
| Chun R. Ding | Open-market sale | Common Stock | 51,125 | $48.88 | $2.50M | |
| Chun R. Ding | Open-market sale | Common Stock | 260,832 | $49.58 | $12.93M | |
| Chun R. Ding | Open-market sale | Common Stock | 27,843 | $50.25 | $1.40M | |
| Joshua J. Ofman - Officer | Open-market sale | Common Stock | 9,692 | $52.00 | $504K | |
| Steven Mizell - Director | Grant or award | Common Stock | 6,082 | $41.10 | $250K | |
| Gregory L. Summe - Director | Grant or award | Common Stock | 6,082 | $41.10 | $250K | |
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 94,035 | $33.93 | $3.19M | |
| Steven Mizell - Director | Grant or award | Common Stock | 760 | $25.94 | $20K | |
| Gregory L. Summe - Director | Grant or award | Common Stock | 1,212 | $25.94 | $31K | |
| Robert P. Ragusa - Officer | Open-market sale | Common Stock | 7,625 | $31.21 | $238K | |
| Aaron Freidin - Officer | Open-market sale | Common Stock | 30,452 | $14.02 | $427K | |
| Joshua J. Ofman - Officer | Grant or award | Stock Option | 63,484 | $0.00 | - | |
| Sarah Krevans - Director | Grant or award | Common Stock | 31,055 | $0.00 | - | |
| William J. Chase - Director | Grant or award | Common Stock | 210 | $13.62 | $3K | |
Item 2.02, 9.01
Item 5.07
Item 5.02, 8.01, 9.01
Item 2.02, 9.01
Recent GRAL Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Andrew Partridge | Officer | 7,873 | $1.15M | View on EDGAR | |
| Aaron Freidin | Officer | 23,619 |
GRAL insider trading FAQ
What is the latest insider trade for GRAL?
GRAIL, Inc. (GRAL) had 6 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for GRAL runs to 70 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GRAL stock?
No insider purchases of GRAL were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling GRAL stock?
15 insider sales of GRAL were filed in the last 90 days, totaling $12.10M.
Where can I see GRAL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GRAL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Andrew John Partridge view on EDGAR
- - Aaron Freidin view on EDGAR
- - Aaron Freidin view on EDGAR
- - Joshua J. Ofman view on EDGAR
- - Joshua J. Ofman view on EDGAR
- - Aaron Freidin view on EDGAR
- - William J. Chase view on EDGAR
- - Gregory L. Summe view on EDGAR
- - Steven Mizell view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where GRAL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GRAL with a 7-day demo
- GRAL on your watchlist
- Every GRAL Form 4 filing on record
- Up to 3 months of GRAL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
